Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ImmunityBio, Inc.
University of Pittsburgh
University of Pittsburgh
Incyte Corporation
Molecular Templates, Inc.
Fate Therapeutics
Incyte Corporation